Strategic Acquisition Channel The Sept 2020 acquisition by Medtronic validates Ellipsys and unlocks access to Medtronic’s global sales network and hospital accounts, accelerating market penetration. BD should align with Medtronic’s vascular access teams to develop a joint value proposition and co-branded materials for nephrology and interventional radiology buyers.

Global Clearance Advantage Ellipsys is FDA approved for pivotal US trials and has CE Mark approval in Europe, enabling expansion into international markets where clearances exist. Focus regional market entry on jurisdictions with regulatory readiness, build regional go-to-market plans, and partner with Medtronic distributors to scale quickly.

Cost Efficiency Ellipsys offers minimally invasive, single-catheter AV fistula creation, potentially reducing procedure time, OR usage, and overall vascular-access costs. Use ROI-driven messaging, case studies, and productivity data to engage dialysis networks, hospitals, and nephrology departments.

Growth Potential With modest current revenue and a history of debt and equity financing, Ellipsys has room for rapid growth backed by Medtronic. Target large multi-site deployments with dialysis providers, offer bundled training and service packages, and leverage Medtronic relationships to broaden reach.

Differentiation Ellipsys’s image-guided percutaneous approach differentiates it from surgical fistula options and bigger competitors. Target early adopters, KOLs, and dialysis networks; propose real-world data programs and multi-center studies to drive adoption within priority markets.